First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Keywords

MedicineNivolumabIpilimumabOpen labelInternal medicineOncologyFirst lineClinical trialSurgeryDermatologyImmunotherapyCancer

Affiliated Institutions

Related Publications

Idiopathic Pulmonary Fibrosis

William W. Douglas , Jay H. Ryu , Darrell R. Schroeder

The clinical records of 487 patients seen at Mayo Clinic Rochester (MCR) during 1994 through 1996 who were diagnosed as having idiopathic pulmonary fibrosis of the usual interst...

2000 American Journal of Respiratory and C... 259 citations

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Matthew D. Hellmann , Luis Paz‐Ares , Reyes Bernabé +23 more

First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...

2019 New England Journal of Medicine 2696 citations

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median ov...

2021 The Lancet 2580 citations

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Howard West , Michael McCleod , Maen Hussein +17 more

Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer ...

2019 The Lancet Oncology 1597 citations

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , George Lau , Masatoshi Kudo +28 more

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion reg...

2022 NEJM Evidence 1193 citations

Publication Info

Year: 2021
Type: article
Volume: 397
Issue: 10272
Pages: 375-386
Citations: 1104
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1104

OpenAlex

Cite This

APA Style

                            
                                
                                    Paul Baas, 
                                
                                    Arnaud Scherpereel, 
                                
                                    Anna K. Nowak
                                
                                et al.
                            
                            (2021). 
                            First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. 
                            The Lancet
                            , 397
                            (10272)
                            , 375-386.
                            https://doi.org/10.1016/s0140-6736(20)32714-8
                        

Identifiers

DOI: 10.1016/s0140-6736(20)32714-8